Tags |
|
|
Links |
|
|
Digg It - Status Quo Pep Talks That Can Threaten Your Leadership
Organizations live and die by results. Yet most organizations get a fraction of the results they are capable of. There are many reasons for this: poor strategy, poor leadership, insufficient resources, etc. But one main reason is overlooked
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
by most leaders. Many organizations stumble because they are permeated with a robust status quo.
The trouble with the status quo isn't that it gets poor results. After all, if you know you're getting poor results, you can do something about
The trouble with the status quo isn't that it gets poor results. After all, if you know you're getting poor results, you can do something about
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
it. You can start taking steps to turn them into good results.
The trouble with the status quo is that it gets mediocre results but represents them as good results. And poor results are less harmful to an organization than mediocre results m
The trouble with the status quo is that it gets mediocre results but represents them as good results. And poor results are less harmful to an organization than mediocre results m
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
srepresented as good results.
The status quo is simply the existing state of an organization. You might ask, "What's wrong with the existing state of an organization?" My response is, "A great deal." In fact, the status quo is always ... no
The status quo is simply the existing state of an organization. You might ask, "What's wrong with the existing state of an organization?" My response is, "A great deal." In fact, the status quo is always ... no
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
t sometimes ... always wrong.
Leadership is not a measure of results. Results are a measure of leadership. A leader should be getting not average results but more results faster, and "more, faster" continually.
The status quo is the enemy o
Leadership is not a measure of results. Results are a measure of leadership. A leader should be getting not average results but more results faster, and "more, faster" continually.
The status quo is the enemy o
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
the "more results faster continually" because the status quo is in business to be the status quo first and get results second. Its number one priority is always self-preservation.
Of course, without the impulse toward self-preservation, orga
Of course, without the impulse toward self-preservation, orga
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
nizations would quickly fall apart. But when the impulse hijacks the need of the organization's leaders to adapt to changing circumstances, the status quo is a threat.
For instance: For years until the mid 20th century, IBM flourished by havi
For instance: For years until the mid 20th century, IBM flourished by havi
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
ng their machines perform calculations using punch cards. But then the digital revolution came along. However, during the late 1940s and early 1950s a strong status quo of employees were wedded to punch cards and were convinced digital would
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
ead to disaster.
As IBM CEO Thomas J. Watson Jr. said in his book, "Father, Son & Co.", "There wasn't a single, solitary soul in the company who grasped even a hundredth of the potential the computer had."
It took his strong leadership to fig
As IBM CEO Thomas J. Watson Jr. said in his book, "Father, Son & Co.", "There wasn't a single, solitary soul in the company who grasped even a hundredth of the potential the computer had."
It took his strong leadership to fig
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
ht off the status quo and move IBM into the digital age. If the status quo had prevailed, IBM would have been out of business in a few years. Still, the status quo put up such a fight that switching the organization from punch cards to digita
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
processes nearly destroyed the company.
The IBM example is not the exception but the rule: The success or failure of any organization hinges to a great extent on how its leaders deal with the status quo.
No question about it, if you try to g
The IBM example is not the exception but the rule: The success or failure of any organization hinges to a great extent on how its leaders deal with the status quo.
No question about it, if you try to g
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
et into the realm of achieving more results faster continually, the status quo will attack you. The question isn't, "If " but "How?" and "When?"
One way it attacks is through status quo pep talks to gain ardent support. When you are ready fo
One way it attacks is through status quo pep talks to gain ardent support. When you are ready fo
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
r them, you are better able to deal with them and get ahead of the curve in thwarting the status quo.
Here are some phrases that may be used in status quo pep talks to rally people against anyone threatening its existence.
"Pretend to go al
"Pretend to go al
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
ng and they'll go away."
"Just do your job and nothing more."
"Agree with anything they say but do what you want to do."
"Let it die a natural death."
"We tried that before and it didn't work."
"I'm too busy."
"Just do your job and nothing more."
"Agree with anything they say but do what you want to do."
"Let it die a natural death."
"We tried that before and it didn't work."
"I'm too busy."
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
"That's not my job."
"Wait ‘em out."
"You're the leader. You take care of it."
"That's not the way we do things."
"You'll ruin this organization."
"You don't understand me."
"You don't understand what I'm do
"Wait ‘em out."
"You're the leader. You take care of it."
"That's not the way we do things."
"You'll ruin this organization."
"You don't understand me."
"You don't understand what I'm do
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
ng."
"You don't understand our organization."
"It's more complicated than you think."
"I'm doing the best I can."
"Give me a break."
"You're not being realistic."
"You'll squeeze me dry."
"Don't you hav
"You don't understand our organization."
"It's more complicated than you think."
"I'm doing the best I can."
"Give me a break."
"You're not being realistic."
"You'll squeeze me dry."
"Don't you hav
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
e better things to do?"
"I've got too much on my plate."
"Don't bust a blood vessel."
"I'll help -- if you do me a favor."
"It's not in my job description."
"It all pays the same."
"Why don't you quit while yo
"I've got too much on my plate."
"Don't bust a blood vessel."
"I'll help -- if you do me a favor."
"It's not in my job description."
"It all pays the same."
"Why don't you quit while yo
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
u're ahead?"
"Let study it some more."
"Don't go off half-cocked."
"Too much, too far, too fast."
"We need more facts."
Now that you have an idea of what the status quo is and how dangerous it can be; don't let
"Let study it some more."
"Don't go off half-cocked."
"Too much, too far, too fast."
"We need more facts."
Now that you have an idea of what the status quo is and how dangerous it can be; don't let
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
ts pep talks dissuade you from your mission as a leader of achieving more results faster continually.
2005 © The Filson Leadership Group, Inc. All rights reserved.
PERMISSION TO REPUBLISH: This article may be republished in newsletters and
2005 © The Filson Leadership Group, Inc. All rights reserved.
PERMISSION TO REPUBLISH: This article may be republished in newsletters and
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
on web sites provided attribution is provided to the author, and it appears with the included copyright, resource box and live web site link. Email notice of intent to publish is appreciated but not required: mail to: brent@actionleadership.co
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.diggit.org.ua/article/23880/diggit-Status-Quo-Pep-Talks-That-Can-Threaten-Your-Leadership.html">Status Quo Pep Talks That Can Threaten Your Leadership</a>
BB link (for phorums):
[url=http://www.diggit.org.ua/article/23880/diggit-Status-Quo-Pep-Talks-That-Can-Threaten-Your-Leadership.html]Status Quo Pep Talks That Can Threaten Your Leadership[/url]
Related Articles:
Three Tough Questions your Business Needs to Answer
Owning A Website For Your Business - Outsourcing Web Design And Webdevelopment
Careers In Psychology-What One Is Right For You
Bookmark it:
|